“Yong” syndrome–cGAS-STING axis: a TCM syndrome-based hypothesis for overcoming primary anti-PD-1 resistance in gastric cancer
Journal for ImmunoTherapy of Cancer · 2026-08 · 14 (8) · e015810
DOI: 10.1136/jitc-2026-015810 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 04.08.2026. Verfasst von Yinghou Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Membrane Proteins, Programmed Cell Death 1 Receptor, Nucleotidyltransferases. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Doctoral Startup Foundation of Liaoning Province, the Key R&D Project of Liaoning Provincial Science and Technology Program.
Abstract (Originalsprache)
Gastric cancer (GC) remains a major clinical challenge, with most patients exhibiting primary resistance to anti-programmed cell death protein-1 (anti-PD-1) immunotherapy and a lack of effective predictive biomarkers. Most advanced GC presents as immune-excluded “cold” tumors that respond poorly to immune checkpoint blockade. Traditional Chinese medicine (TCM) “Yong (abscess)” syndrome and the “treating GC as Yong” theory are widely applied in clinical practice, yet lack clear molecular and immunological mechanisms. Here, by translating these clinical observations into modern biological terms, we present an original, testable hypothesis proposing the “Yong” syndrome–cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) axis as the central molecular bridge connecting TCM syndrome subtypes, GC histological subtypes, and TME reprogramming. We hypothesize that heat-clearing and blood-activating TCM monomers activate cGAS-STING in a subtype-selective manner to convert “cold” tumors to “hot” immunogenic phenotypes, directly addressing the critical clinical dilemmas of primary anti-PD-1 resistance and insufficient biomarkers in GC immunotherapy. This hypothesis translates universal cGAS-STING mechanisms into a clinically actionable, syndrome-based precision strategy for GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China.
- Department of Internal Medicine, Liaoning University of Traditional Chinese Medicine Affiliated Hospital, Shenyang, Liaoning, China.
- Liaoning University of Traditional Chinese Medicine Affiliated Hospital, Shenyang, Liaoning, China.
- Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China cmudoctorzyj@163.com.
Förderung
- Doctoral Startup Foundation of Liaoning Province
- the Key R&D Project of Liaoning Provincial Science and Technology Program
Zitieren
APA
Wang, Y., Liu, G., Li, Y., Zhou, L., Chen, Y., Zhang, Y., Xiao, J., & Zhang, Y. (2026). “Yong” syndrome–cGAS-STING axis: a TCM syndrome-based hypothesis for overcoming primary anti-PD-1 resistance in gastric cancer. Journal for ImmunoTherapy of Cancer, 14(8), e015810. https://doi.org/10.1136/jitc-2026-015810
Vancouver
Wang Y, Liu G, Li Y, Zhou L, Chen Y, Zhang Y, et al. “Yong” syndrome–cGAS-STING axis: a TCM syndrome-based hypothesis for overcoming primary anti-PD-1 resistance in gastric cancer. Journal for ImmunoTherapy of Cancer. 2026;14(8):e015810. doi:10.1136/jitc-2026-015810
BibTeX
@article{Wang2026,
author = {Wang, Yinghou and Liu, Guozheng and Li, Yan and Zhou, Lijie and Chen, Yanyan and Zhang, Ye and Xiao, Jingdong and Zhang, Yajie},
title = {“Yong” syndrome–cGAS-STING axis: a TCM syndrome-based hypothesis for overcoming primary anti-PD-1 resistance in gastric cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {8},
pages = {e015810},
doi = {10.1136/jitc-2026-015810}
}
EUVIMED